Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Notice to Readers: Nosocomial Burkholderia
cepacia Infections Associated with Exposure to Sublingual Probes --- Texas, 2004
Burkholderia cepacia (formerly known as
Pseudomonas cepacia, a gram-negative rod [GNR]) is associated with
nosocomial infections among intensive care unit patients and use of contaminated equipment and solutions
(1--4). In August 2004, the Texas Department of Health received reports of positive cultures for
B. cepacia from respiratory samples of 13 intensive
care unit patients receiving mechanical ventilation at a hospital in Texas during April--August 2004. None of the patients had cystic fibrosis, a condition commonly associated with
B. cepacia. Initial investigation by the hospital's infection-control
team revealed that nearly all of the patients had been exposed to a sublingual probe indicated for use for monitoring tissue carbon dioxide levels. The probe, an SLS-1 Sublingual
Sensor, is part of the Nellcor® CapnoProbe™ Sublingual System(model
N-80 monitor), a Food and Drug Administration (FDA)-regulated medical device (Nellcor, Pleasanton, California). Each probe is packaged in a metal canister filled with a buffered saline solution and sealed in a foil envelope labeled as nonsterile. Each disposable sensor is used only once.
Cultures of the buffered saline solution from at least two lots of unopened probes yielded
B. cepacia and other GNRs. B.
cepacia isolates from some patients and unopened sensor canisters were indistinguishable by pulsed field gel electrophoresis analysis at the Texas Department of Health laboratory. Investigations into other reports of
B. cepacia and other GNRs that might be associated with use of such probes is
ongoing at hospitals in Texas and California. The manufacturer has issued
a voluntary recall of all SLS-1 Sublingual Sensors.
Clinicians should be aware that patients exposed to these probes might have been exposed to various GNRs, including
B. cepacia. Recovery of B. cepacia or GNRs that might be related to use of a sublingual carbon dioxide probe should be reported to state health departments and CDC's Division of Healthcare Quality and Promotion, telephone 800-893-0485.
Health-care facilities are encouraged to report through the FDA's voluntary MedWatch reporting program any events not
reported under the mandatory process. Additional information is available at
http://www.fda.gov/cdrh/mdr/index.html or telephone 800-FDA-1088. Users of this probe should return existing inventory of unused SLS-1 Sublingual Senors by contacting
Nellcor's Technical Services department, telephone 800-635-5267, option 3.
Reported by:P Metcalf, K Newman, JD Siegel, MD, Children's Medical Center, Dallas; N Pascoe, Texas Dept of Health. D Terashita, MD, L Mascola, MD, Los Angeles County Dept of Health Svcs, California. A Srinivasan, MD, M Arduino, PhD, Div of Healthcare Quality
Promotion, National Center for Infectious Diseases; R Taylor, PhD, EIS Officer, CDC.
References
CDC. Manufacturer's recall of nasal spray contaminated with
Burkholderia cepacia complex. MMWR 2004;53:246.
Nasser RM, Rahi AC, Haddad MF, Daoud Z, Irani-Hakime N, Almawi WY. Outbreak of
Burkholderia cepacia bacteremia traced to
contaminated hospital water used for dilution of an alcohol skin antiseptic.
Infect Control Hosp Epidemiol 2004;25:189--91.
Shehabi AA, Abu-Al-Soud WA, Mahafzah A, et al. Investigation of
Burkholderia cepacia nosocomial outbreak with high fatality in patients suffering from diseases other than cystic fibrosis. Scand J Infect Dis 2004;36:174--8.
LiPuma JJ. Burkholderia cepacia epidemiology and pathogenesis: implications for infection control. Curr Opin Pulm Med 1998;4:337--41.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
